Norge -
norsk -
Statens legemiddelverk
jext 300 mikrog
alk-abelló as - adrenalintartrat - injeksjonsvæske, oppløsning i ferdigfylt penn - 300 mikrog
Norge -
norsk -
Statens legemiddelverk
jext 150 mikrog
alk-abelló as - adrenalintartrat - injeksjonsvæske, oppløsning i ferdigfylt penn - 150 mikrog
Norge -
norsk -
Statens legemiddelverk
smofkabiven extra nitrogen
fresenius kabi norge as - aminosyrer, uspesifisert / elektrolytter / glukose / fettemulsjon - infusjonsvæske, emulsjon
Norge -
norsk -
Statens legemiddelverk
smofkabiven extra nitrogen electrolyte free
fresenius kabi norge as - aminosyrer, uspesifisert / glukose / fettemulsjon - infusjonsvæske, emulsjon
Den europeiske union -
norsk -
EMA (European Medicines Agency)
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neuromuskulær blokkade - alle andre terapeutiske produkter - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
lacosamide adroiq
extrovis eu ltd. - lakosamid - epilepsi - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.